Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
Jens Lundgren, Birgit Grund, Christina E. Barkauskas, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 10, pp. 905-914
Open Access | Times Cited: 427

Showing 1-25 of 427 citing articles:

Adaptive immunity to SARS-CoV-2 and COVID-19
Alessandro Sette, Shane Crotty
Cell (2021) Vol. 184, Iss. 4, pp. 861-880
Open Access | Times Cited: 1749
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Elisabetta Cameroni, John E. Bowen, Laura E. Rosen, et al.
Nature (2021) Vol. 602, Iss. 7898, pp. 664-670
Open Access | Times Cited: 1106
A living WHO guideline on drugs for covid-19
Arnav Agarwal, Beverley J. Hunt, Miriam Stegemann, et al.
BMJ (2020), pp. m3379-m3379
Open Access | Times Cited: 962
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Zhuoming Liu, Laura A. VanBlargan, Louis-Marie Bloyet, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 3, pp. 477-488.e4
Open Access | Times Cited: 809
Neutralizing monoclonal antibodies for treatment of COVID-19
Peter C. Taylor, Andrew C. Adams, Matthew M. Hufford, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 6, pp. 382-393
Open Access | Times Cited: 706
SARS-CoV-2 pathogenesis
Mart M. Lamers, Bart L. Haagmans
Nature Reviews Microbiology (2022) Vol. 20, Iss. 5, pp. 270-284
Open Access | Times Cited: 685
Tackling COVID-19 with neutralizing monoclonal antibodies
Davide Corti, Lisa A. Purcell, Gyorgy Snell, et al.
Cell (2021) Vol. 184, Iss. 12, pp. 3086-3108
Open Access | Times Cited: 369
Severe covid-19 pneumonia: pathogenesis and clinical management
Amy Attaway, Rachel G. Scheraga, Adarsh Bhimraj, et al.
BMJ (2021), pp. n436-n436
Open Access | Times Cited: 366
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2022) Vol. 399, Iss. 10325, pp. 665-676
Open Access | Times Cited: 354
Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic
Kelvin Kai‐Wang To, Siddharth Sridhar, Kelvin Hei‐Yeung Chiu, et al.
Emerging Microbes & Infections (2021) Vol. 10, Iss. 1, pp. 507-535
Open Access | Times Cited: 297
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
Florian A. Lempp, Leah Soriaga, Martin Montiel-Ruiz, et al.
Nature (2021) Vol. 598, Iss. 7880, pp. 342-347
Closed Access | Times Cited: 293
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Deborah Cromer, Jennifer A. Juno, David S. Khoury, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 6, pp. 395-404
Open Access | Times Cited: 258
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
Rita E. Chen, Emma S. Winkler, James Brett Case, et al.
Nature (2021) Vol. 596, Iss. 7870, pp. 103-108
Open Access | Times Cited: 251
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
Jeffrey A. Sparks, Zachary S. Wallace, Andrea M. Seet, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 9, pp. 1137-1146
Open Access | Times Cited: 212
Monoclonal antibody therapies against SARS-CoV-2
Daniele Focosi, Scott A. McConnell, Arturo Casadevall, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 11, pp. e311-e326
Open Access | Times Cited: 204
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
James D. Chalmers, Megan Crichton, Pieter Goeminne, et al.
European Respiratory Journal (2021) Vol. 57, Iss. 4, pp. 2100048-2100048
Open Access | Times Cited: 201
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Yu‐Chyi Hwang, Ruei‐Min Lu, Shih-Chieh Su, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 194
SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
Alona Kuzmina, Yara Khalaila, Olga Voloshin, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 4, pp. 522-528.e2
Open Access | Times Cited: 192
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
Wesley H. Self, Uriel Sandkovsky, Cavan Reilly, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 5, pp. 622-635
Open Access | Times Cited: 182
Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy
Rachel Yamin, Andrew Jones, Hans-Heinrich Hoffmann, et al.
Nature (2021) Vol. 599, Iss. 7885, pp. 465-470
Open Access | Times Cited: 162
A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19
Max R. O’Donnell, Beatriz Grinsztejn, Matthew J. Cummings, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 13
Open Access | Times Cited: 160
The development of COVID-19 treatment
Yongliang Yuan, Baihai Jiao, Lili Qu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 150
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up
Colin Baigent, Stephan Windecker, Daniele Andreini, et al.
European Heart Journal (2021) Vol. 43, Iss. 11, pp. 1059-1103
Open Access | Times Cited: 147
COVID-19 therapeutics: Challenges and directions for the future
Philip C. Robinson, David Liew, Helen Tanner, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 15
Open Access | Times Cited: 142
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Peter Horby, Marion Mafham, Leon Peto, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 139
Page 1 - Next Page

Scroll to top